Raised more than 140 million yuan in financing in three months.
It is reported that the third-party medical testing platform ” Jiajian Medical “ recently completed the B round of financing, this round of financing amounted to more than 110 million yuan. The leading investor is Songhe Capital, and the investors are Zhiyuan Xinxing, Qianfeng No.1, and Jiarui Medical.
In October 2019, Jiajian Medical has just completed a 30 million A + round of financing. As a result, Jiajian Medical raised more than 140 million yuan in three months.
Jiajian Medical was established by Chinese clinical genetic counseling experts Professor Lu Guohui and Professor Zhang Wei to provide personalized comprehensive diagnosis of genetic diseases and tumors and clinical genetic counseling services.
Image from Jiajian Medical Official Website
The company is currently the only independent medical service organization in the country that has three professional qualifications certified by the American Medical Genetics Association (ABMG). The three majors include clinical cytogenetics, clinical biochemical genetics, and clinical molecular genetics.
The core products provided by Jiajian Medical are genetic testing, including: high-precision clinical display PLUS, STACTare project (7 days report), “gold standard” for mitochondrial disease detection, 21-hydroxylase deficiency, autosomal Dominant polycystic kidney disease, facial and shoulder brachial muscular dystrophy test, chromosome test, etc. Compared with the conventional testing scheme, Jiajian Medical emphasizes that the company uses a new patented testing scheme, which is faster, more comprehensive, and lower in price.
Jiajian Medical’s products-high-precision clinical display PLUS
Data display In recent years, global genetic testing has grown at a rate of 20%, and it is expected that the growth rate of the industry in the future will also remain at about 18%.
There are two key reasons for the commercialization of genetic testing. First, the price of genetic testing has dropped dramatically . At the beginning of the century, measuring a person’s genome cost nearly $ 100 million, and With the advancement of sequencing technology, the price has dropped to nearly $ 1,000 in 2017.
Second, a large number of new treatments have appeared in the field of tumor immunity in recent years (such as PD-1 / PD-L1 on the tuyere), but the activation of the immune system may also bring side effects such as myocarditis.
At present, the genetic testing track is already in competition among giants. Star companies include BGI, Boao Bio, Berry and Kang, Nuohe Zhiyuan, Carbon Cloud Intelligence, Shihe Gene, Pansheng, Jiyin Plus wait.